Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America

Italfarmaco and JCR entered an exclusive licensing agreement for the development and commercialization of JR-141 across the United States, Europe, and Latin America. The deal expands JR-141's potential geographic reach in major pharmaceutical markets, though no financial terms, development timeline, or regulatory details were disclosed.